Hoʻolaha ʻia

Hāʻawi ʻo BMKGENE i nā lawelawe hi-C sequencing no kēia noiʻi: ʻO ka disorganization 3D a me ka hoʻonohonoho hou ʻana o ka genome e hāʻawi i nā ʻike i ka pathogenesis o ka maʻi momona momona ʻole (NAFLD) e ka hoʻohui ʻana o Hi-C, Nanopore, a me RNA, i paʻi ʻia ma Acta Pharmaceutica Sinica B.

I loko o kēia haʻawina, High-throughput chromosome conformation capture (Hi-C), Nanopore sequencing, a me RNA-sequencing (RNA-seq) assays i hana ʻia ma ke ake o nā ʻiole maʻamau a me NAFLD.

ʻIke ʻia nā ʻano like ʻole ma nā tausani o nā ʻāpana o ka genome e pili ana i ka hui chromatin 3D a me ka hoʻonohonoho hou ʻana o ka genomic, ma waena o nā ʻiole maʻamau a me NAFLD, a hōʻike ʻia ka dysregulation gene i hele pū ʻia me kēia mau ʻano.Ua ʻike ʻia nā genes target moho ma NAFLD, i hoʻopilikia ʻia e ka hoʻoponopono hou ʻana a me ka hoʻohaunaele ʻana o ka hui spatial.

Hāʻawi nā ʻike hou i nā ʻike i nā mīkini hou o NAFLD pathogenesis a hiki ke hāʻawi i kahi ʻano manaʻo noʻonoʻo hou no ka NAFLD therapy.

Kaomimaaneie aʻo hou e pili ana i kēia haʻawina.